The nitric oxide synthase inhibitor, L-NAME, blocks phencyclidine-induced disruption of prepulse inhibition in mice

被引:51
|
作者
Klamer, D [1 ]
Engel, JA [1 ]
Svensson, L [1 ]
机构
[1] Univ Gothenburg, Dept Pharmacol, S-40530 Gothenburg, Sweden
关键词
nitric oxide; prepulse inhibition; schizophrenia; phencyclidine; mice;
D O I
10.1007/s002130100783
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Rationale: Schizophrenia is a major public health problem that affects approximately 1% of the population worldwide. Schizophrenia-like syndromes can be induced in humans by phencyclidine (PCP), a drug with marked psychomimetic properties. Recent studies show that the behavioural and biochemical effects of PCP in rats are blocked by nitric oxide synthase (NOS) inhibitors, suggesting that NO plays an important role in the pharmacological effects of PCP. Objective: The aim of this study was to investigate if PCP-induced disruption of prepulse inhibition of acoustic startle could be blocked by the NOS inhibitor, L-NAME, in mice. Results: The present study shows that PCP readily disrupts prepulse inhibition in mice normally without affecting pulse-alone trials. Furthermore, L-NAME blocked the PCP-induced disruption of prepulse inhibition in a dose-related manner. Conclusions: The PCP-induced disruption of prepulse inhibition and the ability of L-NAME to block this effect in both rats and mice suggest that this is a general and not a species-specific effect. The results of the present study further suggest that PCP exerts at least some of its actions in the central nervous system by a NO-dependent mechanism.
引用
收藏
页码:182 / 186
页数:5
相关论文
共 50 条
  • [21] Lack of phencyclidine-induced effects in mice with reduced neuronal nitric oxide synthase
    Bird, DC
    Bujas-Bobanovic, M
    Robertson, HA
    Dursun, SM
    PSYCHOPHARMACOLOGY, 2001, 155 (03) : 299 - 309
  • [22] L-NAME, a nitric oxide synthase inhibitor, modulates cholinergic antinociception
    Jain, NK
    Kulkarni, SK
    METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, 1999, 21 (03): : 161 - 165
  • [23] Lack of phencyclidine-induced effects in mice with reduced neuronal nitric oxide synthase
    Bird D.C.
    Bujas-Bobanovic M.
    Robertson H.A.
    Dursun S.M.
    Psychopharmacology, 2001, 155 (3) : 299 - 309
  • [24] Cardiomyoctye hypertrophy following inhibition of nitric oxide synthase by l-NAME
    Bell, D
    Kelso, EJ
    Rush, L
    Lamont, V
    McDermott, BJ
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2004, 36 (05) : 715 - 715
  • [25] CLOZAPINES EFFECTS ON PHENCYCLIDINE-INDUCED DISRUPTION OF PREPULSE INHIBITION OF THE ACOUSTIC STARTLE RESPONSE
    WILEY, JL
    PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 1994, 49 (04) : 1025 - 1028
  • [26] Nitric oxide synthase inhibitor (L-NAME) impair the diaphragm function in rat
    Sugiuchi, N
    Takagi, S
    Kikuchi, S
    Seki, I
    Aoki, T
    10TH ASEAN CONGRESS OF ANAESTHESIOLOGISTS / 2ND MEETING OF ASIAN SOCIETY OF CARDIOTHORACIC ANAESTHESIA, 1997, : 165 - 168
  • [27] The vasoconstrictor effects of L-NAME, a nitric oxide synthase inhibitor, in pregnant rabbits
    Losonczy, G
    Mucha, I
    Muller, V
    Kriston, T
    Ungvari, Z
    Tornoci, L
    Rosivall, L
    Venuto, R
    BRITISH JOURNAL OF PHARMACOLOGY, 1996, 118 (04) : 1012 - 1018
  • [28] Cardiorespiratory impact of the nitric oxide synthase inhibitor L-NAME in the exercising horse
    Kindig, CA
    Gallatin, LL
    Erickson, HH
    Fedde, MR
    Poole, DC
    RESPIRATION PHYSIOLOGY, 2000, 120 (02): : 151 - 166
  • [29] Prefrontal GABAB Receptor Activation Attenuates Phencyclidine-Induced Impairments of Prepulse Inhibition: Involvement of Nitric Oxide
    Fejgin, Kim
    Palsson, Erik
    Wass, Caroline
    Finnerty, Niall
    Lowry, John
    Klamer, Daniel
    NEUROPSYCHOPHARMACOLOGY, 2009, 34 (07) : 1673 - 1684
  • [30] Prefrontal GABAB Receptor Activation Attenuates Phencyclidine-Induced Impairments of Prepulse Inhibition: Involvement of Nitric Oxide
    Kim Fejgin
    Erik Pålsson
    Caroline Wass
    Niall Finnerty
    John Lowry
    Daniel Klamer
    Neuropsychopharmacology, 2009, 34 : 1673 - 1684